Russian-backbone LAIV history and clinical development. L.Rudenko Institute of Experimental Medicine, St. Petersburg, Russia
|
|
- Brandon Walton
- 5 years ago
- Views:
Transcription
1 Russian-backbone LAIV history and clinical development L.Rudenko Institute of Experimental Medicine, St. Petersburg, Russia
2 EFFECTIVENESS OF LIVE COLD-ADAPTED INFLUENZA VACCINE FOR ADULTS. SUMMARY FROM 126 TRIALS (500 to 45,000 adults per trial; total > 500,000 adults) Efficacy was confirmed for each trial. Mean effectiveness for 126 trials was = 45.0%.
3 EFFECTIVENESS OF LIVE COLD-ADAPTED INFLUENZA VACCINE DURING THE CIRCULATION OF DRIFTED VARIANT OF INFLUENZA Year Age of vaccines No. of vaccinated children Circulated epidemic strain Vaccine components Effectiveness (%) (95% CI) Alma-Ata, Kazakhstan 3-14 Vaccine Placebo A/Taiwan/1/86 (H1N1) A/Brazil/11/78 (H1N1) A/Philippines/2/82 (H3N2) 27.6 ( ) Alma-Ata, Kazakhstan 3-14 Vaccine Placebo A/Taiwan/1/86 (H1N1) B/Victoria/2/87 A/Taiwan/1/86 (H1N1) A/Philippines/2/82 (H3N2) 34.7 ( ) Velikij Novgorod 7-14 Vaccine 4693 Placebo 4168 A/Shanghai/16/89 (H3N2) A/Taiwan/1/86 (H1N1) A/Sichuan/2/87 (H3N2) B/USSR/3/ ( ) Velikij Novgorod 7-14 Vaccine 5288 Placebo 6385 A/Taiwan/1/86 (H1N1) B/Victoria/2/87 B/Yamagata/16/88 A/Taiwan/1/86 (H1N1) A/Shanghai/11/87 (H3N2) B/USSR/3/ ( ) Velikij Novgorod 7-14 Vaccine 3403 Placebo 3022 A/Beijing/32/92 (H3N2) A/Taiwan/1/86 (H1N1) A/Shanghai/11/87 (H3N2) B/Beijing/203/ ( ) St.Petersburg Region 7-14 Vaccine 554 Placebo 1265 A/New Caledonia/20/99 (H1N1) A/Beijing/262/95 (H1N1) A/Sydney/5/97 (H3N2) B/St.Petersburg/95/ ( ) St.Petersburg Vaccine 539 Placebo 297 A/Wyoming/3/03 (H3N2) A/New Caledonia/20/99 (H1N1) A/Panama/99/242 (H3N2) B/Victoria/2/ ( )
4 EFFICACY OF LIVE ATTENUATED INFLUENZA VACCINE (LAIV) IN CHILDREN 7-14 YEARS OLD (SEROLOGICAL AND VIROLOGICAL CONFIRMATION) LAIV Infuenza morbidity in vaccinees - 5.3% Influenza morbidity in placebo group % Placebo Coefficient of efficacy %
5 Vaccine efficacy for completely vaccinated children, 1 January through 4 March 1990 Vaccine group No. of vaccinated Morbidity in epidemic season (No. of cases / %) Efficacy % (95% confidence interval) Live / 13.0 Inactivated / ( ) 29.6 ( ) Placebo / 27.0
6 Efficacy live influenza vaccine against school absence due to physician-diagnosed influenza or acute respiratory disease and against 4-fold rise in antibody titer to influenza A (H3N2), Vologda, Russia, 1 January to 2 February 1992 Absence No./Total (%) Efficacy measure Placebo Live Influenza Vaccine 18/187 (9.6) 10/196 (5.1) Relative risk/vaccine efficacy (%) */47 4-fold antibody rise No./Total (%) 37/163 (23) 10/160 (6) Relative risk/vaccine efficacy (%) **/72 * P=0.06 vs. placebo (Fisher's exact test, one-tailed) ** P<0.001 vs. placebo Vaccine strains: A/Leningrad/92/89(H1N1), A/Zakharpatije/354/89(H3N2), B/Yamagata/16/98 Circulated epidemic strain: A/Beijing/353/89 (H3N2) Khan AS, Polezhaev F, Vasiljeva R, Drinevsky V, Buffington J, Gary H, Sominina A, Keitel W, Regnery H, Lonskaya NL, Doroshenko E, Gavrilov A, Ivakhov I, Arden N, Schonberger LB, Couch R, Kendal A, Cox N. Comparison of US inactivated split-virus and Russian live attenuated, cold-adapted trivalent influenza vaccines in Russian schoolchildren. The Journal of Infectious Diseases. 1996;173(2):453-6.
7 LONG-TERM PROTECTION AGAINST INFLUENZA AMONG CHILDREN 16 MONTHS POST-VACCINATION BY LAIV ( ) No. of City Velikij Novgorod vaccinated children Vaccine Placebo Effectiveness % 42.1 Vaccine strain - A/Shanghai/11/87 (H3N2)-like Circulated epidemic strain - A/Beijing/32/92 (H3N2)
8 INDIRECT PROTECTION I. Kaliningrad clinical trial children 3-6 years old received 2 doses of vaccine or placebo. The high level of vaccination is required to induce indirect protection. Percent of Vaccinated Illness, % 20,0 30,0 67,6 8,0 81,6 2,5 II % of protection of Smolensk region from were twice vaccinated with LIV. Two nearby control towns Kaluga and Vitebsk were not vaccinated. Thus the 5 year study showed that large scale vaccination with LIV is an effective, economical and expedient means of influenza control. III. As shown by the Novgorod school study, in which it was observed that influenza morbidity was significantly lower amoong non-vaccinated pupils and staff, where more than 50% pupils were vaccinated, compared with those schools, where pupils received inactivated influenza vaccine.
9 PERCENT OF CHILDREN WHO RECEIVED LIVE VACCINE IN EACH SCHOOL VS. PERCENT OF STAFF WHO WERE ILL IN THAT SCHOOL, Percent by school of children vaccinated with live vaccine Percent ill in staff Rudenko LG, Slepushkin AN, Monto AS, Kendal AP, Grigorieva EP, Burtseva EP, Rekstin AR, Beljaev AL, Bragina VE, Cox N, Ghendon YZ, Alexandrova GI. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. The Journal of Infectious Diseases. 1993;168(4):881-7.
10 REGRESSION ANALYSIS RELATING VACCINATION RATE IN SCHOOL IN WHICH CHILDREN RECEIVED VACCINE OR PLACEBO TO PROPORTION ILL IN UNVACCINATED CHILDREN OR STAFF Vaccine group β (95% confidence interval) r 2 % of ill staff vs. % of students vaccinated Live (-1.82, -1.15) 0.86 Inactivated (-0.72, 0.26) 0.11 Placebo (-0.65, 0.25) 0.07 % of ill nonvaccinated children vs. % of students vaccinated Live (-1.15, -1.63) 0.51 Inactivated 0.04 (-0.38, 0.46) 0.00 Placebo (-0.91, 0.41) 0.06 Rudenko LG, Slepushkin AN, Monto AS, Kendal AP, Grigorieva EP, Burtseva EP, Rekstin AR, Beljaev AL, Bragina VE, Cox N, Ghendon YZ, Alexandrova GI. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. The Journal of Infectious Diseases. 1993;168(4):881-7.
11 LIST OF PANDEMIC LAIVs PREPARED ON A/LENINGRAD/134/17/57 (H2N2) BACKBONE Vaccine strain Subtype Wild-type parental virus The stage of study A/17/duck/Potsdam/86/92 H5N2 A/duck/Potsdam/1402-6/86 (H5N2)** Phases I and II clinical trials completed The vaccine is registered in Russia А/17/California/2009/38 H1N1 A/California/07/2009(H1N1)* Phases I and II clinical trials completed The vaccine is registered in Russia, Thailand, India А/17/mallard/Netherlands/ 00/95 H7N3 А/mallard/Netherlands/12/ 2000 (H7N3)* Phase I clinical trial completed А/17/turkey/Turkey/05/133 H5N2 A/turkey/Turkey/1/2005 (H5N1), clade 2.2** Phase I clinical trial completed A/17/Vietnam/04/65107 H5N2 A/Vietnam/1203/2004 (H5N1) clade 1** Studied in animal models cavn1203-len17rg H5N1 A/Egypt/321/2007 (H5N1) clade 2.2* Studied in animal models caeg321-len17rg H5N1 A/Vietnam/1203/2004 (H5N1) clade 1* Studied in animal models А/17/California/66/395 H2N2 А/California/1/66 (H2N2)* Phase I clinical trial completed A/17/Tokyo/67/326 H2N2 A/Tokyo/3/67/326 (H2N2)* Studied in animal models А/17/Anhui/2013/61 H7N9 А/Anhui/1/2013 (H7N9)* Phase I clinical trial completed *Vaccine strain inherited HA and NA genes from wild-type parental virus and remaining six genes from master donor virus, i.e., 6:2 genetic formula. **Vaccine strain inherited only HA gene from wild-type parental virus and remaining seven genes from master donor virus, that is, 7:1 genetic formula.
12 Methods for study immunogenicity of LAIV Serum hemagglutinating antibodies in HAI test Serum neutralizing antibodies in MN test IgA, IgG serum specific (ELISA) Secretory IgA in nasal swabs (ELISA) Is highly desirable study of CMI by methods of flow cytometry and ELISPOT
13 SERUM ANTIBODY IMMUNE RESPONSES BEFORE AND AFTER ADMINISTRATION OF H7N9 LAIV OR PLACEBO Reciprocal geometric mean titers Haemagglutinin inhibition (95% CI) Placebo (n=10) Vaccine (n=29) Baseline P value Microneutralization (95% CI) Placebo (n=10) Vaccine (n=29) P value 3.3 ( ) 3.0 ( ) ( ) 5.2 ( ) 0.88 Participants with titers 1/40 0% (0-31) 0% (0-12) - 0% (0-31) 0% (0-31) - Reciprocal geometric mean titer Participants with seroconversion Reciprocal geometric mean titer in participants with seroconversion 28 days after dose ( ) 5.1 ( ) ( ) 17.7 ( ) % (0-31) 10% (2-27) % (0-31) 48% (29-68) NA NA 44.2 ( ) - Participants with titers 1/40 0% (0-31) 0% (0-12) - 0% (0-31) 38% (21-58) Reciprocal geometric mean titer Participants with seroconversion Reciprocal geometric mean titer in participants with seroconversion 28 days after dose ( ) 10.2 ( ) ( ) 27.3 ( ) % (0-31) 66% (46-82) % (0-31) 72% (53-87) NA 17.3 ( ) - NA 45.6 ( ) - Participants with titers 1/40 0% (0-31) 14% (4-32) % (0-31) 59% (39-77) 0.002
14 Antibody immune responses to H5N1 IIV among individuals previously primed with H5N2 LAIV (compared to unprimed control) Antigen % seroconverted LAIV primed (n=19) Unprimed control (n=24) Day 7 Day 28 Day 7 Day 28 GMT % seroconverted HAI assay GMT % seroconverted GMT % seroconverted t/turkey (H5N2) LAIV NIBRG-23 (H5N1) A/Indonesia/5/05 (PR8- based) A/duck/Potsdam (H5N2) LAIV Microneutralization assay t/turkey (H5N2) LAIV NIBRG-23 (H5N1) GMT H5N2 LAIV primed for a robust recall response after a later alum-adjuvanted H5N1 IIV vaccination
15 Comparison of H1N1pdm LAIVs This slide summarizes some features of LAIV reassortants prepared on the Len/17 and Ann Arbor backbones. Some key amino acids in HA and virus titers in eggs, MDCK cells and mouse URT are shown. Original LAIV based on California strain had good growth characteristics, but the virus had Glutamic acid (E) at position 47, and this made the virus unstable. Our colleagues from Medimmune made mutagenesis of HA to improve virus growth characteristics, and the key positions were 222, 223. Although more recent Bolivia strain was more stable due to K-47 residue, the LAIV based on this virus grew poorly in MDCK cells and didn t replicate in mouse nasal turbinates. We introduced two mutations at positions 222/223 (as was done by MedImmune) but the virus still grew poorly in mammalian cells. Only the LAIVs prepared from two recent strains (South Africa and New York) replicated well in cells and mouse tissues. We suggest that the key position might be E-127. This mutation was seen by other researchers when they adapted California virus to mice, and the D-127- E mutation enhanced virus growth in mouse tissues. Surface genes of LAIV strain A/California/7/ 2009 (Len17: IEM) A/California/7/ 2009 (AA: mut- MedImmune* A/Bolivia/559/ 3013 (Len17: IEM) A/Bolivia/559/ 3013 (Len17: mut-iem) RG A/South Africa/3626/20 13 (Len17: CDC) A/New York/61/2015 (Len17: IEM) clade HA2 47 HA1 127 HA1 222 HA1 223 Titer of LAIV strain (ml -1 ) eggs MDCK cells mouse NT - E D D R E D G Q 7.4? 4.0 6b K D D R <1.1 6b K D G Q <1.1 6b K E D Q b.2 K E N Q n.d. *enhanced growth in eggs (Chen et al, JVI 2010) D127E mutation enhanced H1N1 viral growth in mouse tissues (Sakabe et al, Virus Res 2011 E47K (HA2) mutations enhances temperature and ph stability of HA (Cotter et al, PLoS PATH, 2014)
16 NP gene major target for CTL response CTLs targeted to some NP epitopes of Len/17 MDV do not recognize NP of currently circulated influenza A viruses Inclusion of NP from currently circulated influenza A viruses into LAIV formulation would bring advantages in terms of CTL response wt NP is the best candidate for inclusion into LAIV 5:3 reassortants Rimmelzwaan GF, Kreijtz JH, Bodewes R, Fouchier RA, Osterhaus AD. Influenza virus CTL epitopes, remarkably conserved and remarkably variable. Vaccine Oct 23;27(45):
17 In vivo killing activity of CTLs induced by 6:2 or 5:3 LAIVs This slide shows the in vivo killing activity of mouse CTLs induced after immunization with 6:2 or 5:3 LAIV reassortants. We prepared two pairs of reassortants of H7N9 (left graph) and H1N1 subtype (right graph). Each dot shows the proportion of survived target cells (mouse splenocytes) loaded with wild-type virus (or specific NP epitope of wild-type virus) after intravenous inoculation into immunized mice. For H7N9 viruses, only in 5:3-immunized mice these target cells loaded with NP epitope of wt virus were effectively killed by CTLs, whereas no difference were seen for 6:2 LAIV. For H1N1 viruses, where the target cells were loaded with whole wild-type virus, the effect was the same: only CTLs of 5:3-immunized mice could effectively kill these target cells. These data confirm that 5:3 reassortant LAIV induce more relevant CTL immunity, compared to 6:2 LAIV.
18 Cross-protection afforded by 6:2 or 5:3 LAIVs Both LAIV pairs protected animals from homologous challenge. But consistent with the previous slide, the 5:3 LAIV reassortants protected immunized mice better against heterologous challenge. For H7N9 LAIVs we used two viruses for challenge experiments: avian H7N3 virus and PR8-based reassortant with NP gene from H7N9 virus. For both viruses viral titers in lungs were reduced, compared to controls, only in mice immunized with 5:3 LAIV. For H1N1 viruses, a virus A/New York/2014 and PR8-based reassortant with NP gene from South Africa/2013 virus were used as heterologous challenge. For New York challenge viral titers in lungs were reduced compared to control only for 5:3 LAIV (but not 6:2). For PR8 challenge both vaccines reduced pulmonary titers, but titers in 5:3 LAIV were significantly lower than in 6:2 LAIV group. These data suggest that the wild-type NP protein incorporated into LAIV genome has significant impact on the induction of cell-mediated immunity, and as a consequence on the vaccine s cross-protection.
19 Summary Overall, it is clear that we need to make the LAIV better, and to improve the performance of current LAIVs we should do the following: Pay more attention to the selection of influenza viruses for generating LAIV reassortants; perform thorough analysis of the LAIV candidates, i.e. study their growth properties in cell cultures and in animal models. Use standardized immunological assays to measure LAIV immunogenicity, i.e. include measuring siga antibody and cellmediated immunity. Modify genome structures of LAIV reassortant viruses, i.e. include additional wild-type gene (NP) into LAIV viruses: from 6:2 genome composition towards 5:3. Develop better stabilizers used for LAIV manufacturing, to improve LAIV stability during storage, shipment and application. Use the most recent advances in the development of influenza vaccines inducing cross-reactive and long-lasting immunity (towards the universal LAIV).
Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine
Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine Irina Isakova-Sivak, PhD Institute of Experimental Medicine, Saint Petersburg, Russia The
More informationStudying Repeated Immunization in an Animal Model. Kanta Subbarao Laboratory of Infectious Diseases, NIAID
Studying Repeated Immunization in an Animal Model Kanta Subbarao Laboratory of Infectious Diseases, NIAID Animal models in Influenza Research Commonly used Mice Ferrets Guinea pigs Non human primates Less
More informationIMMUNOMODULATING EFFECT OF LYPRINOL IN HUMANS VACCINATED WITH LIVE INFLUENZA VACCINE. Larisa G.Rudenko a
1 IMMUNOMODULATING EFFECT OF LYPRINOL IN HUMANS VACCINATED WITH LIVE INFLUENZA VACCINE Anatoly N.Naykhin a *, Andrei R. Rekstin a, Svetlana A.Donina a, Julia A.Desheva a, Elena P.Grigorieva a, Irina B.Barantseva
More informationVaccine 30 (2012) Contents lists available at SciVerse ScienceDirect. Vaccine. jou rn al h om epa ge:
Vaccine 30 (2012) 7395 7399 Contents lists available at SciVerse ScienceDirect Vaccine jou rn al h om epa ge: www.elsevier.com/locate/vaccine Possible outcomes of reassortment in vivo between wild type
More informationPATH Influenza Vaccine Projects
PATH Influenza Vaccine Projects Overview John W. Boslego, MD John Boslego Director, Vaccine Development Global Program March 25 th, 2014 Influenza Vaccine Project (IVP) at PATH IVP Goal: Advance the development
More informationLive Attenuated Influenza Vaccine. I. Background and Seasonal Vaccine
Live Attenuated Influenza Vaccine I. Background and Seasonal Vaccine Influenza infection stimulates multiple arms of the immune system Systemic antibody to HA and NA, and multiple internal proteins Mucosal
More informationHAI and NAI as Correlates of Protection After Influenza Vaccination
HAI and NAI as Correlates of Protection After Influenza Vaccination Arnold S. Monto Thomas Francis Jr. Professor University of Michigan School of Public Health Ann Arbor, Michigan Having Correlates is
More informationH5N1 and H7 LAIV-IAV Prime-Boost Studies
NIAID H5N1 and H7 LAIV-IAV Prime-Boost Studies Kanta Subbarao, MD, MPH NIAID, NIH The LID Pandemic Influenza Vaccine Program Program: CRADA with MedImmune Clinical Trials: Center for Immunization Research,
More informationOriginal Article Development and Sequence Analysis of a Cold-Adapted Strain of Influenza A/New Caledonia/20/1999(H1N1) Virus
Iranian Journal of Virology 2011;5(4): 6-10 2011, Iranian Society for Virology Original Article Development and Sequence Analysis of a Cold-Adapted Strain of Influenza A/New Caledonia/20/1999(H1N1) Virus
More informationApplication of Reverse Genetics to Influenza Vaccine Development
NIAID Application of Reverse Genetics to Influenza Vaccine Development Kanta Subbarao Laboratory of Infectious Diseases NIAID, NIH Licensed Vaccines for Influenza Principle: Induction of a protective
More informationDevelopment of influenza vaccine production by means of chromatographic methods
Development of influenza vaccine production by means of chromatographic methods WHO meeting on prospects for influenza vaccine technology transfer to vaccine manufacturers of developing countries. 27-28
More informationExperiences with Live Attenuated Avian Influenza Vaccine Trials in Thailand
Experiences with Live Attenuated Avian Influenza Vaccine Trials in Thailand Punnee Pitisuttithum, MBBS,DTM&H,FRCPT Vaccine Trial Center,Faculty of Tropical Medicine, Mahidol University For MOPH,CDC,MU,Geneva
More informationUpdate on influenza monitoring and vaccine development
Update on influenza monitoring and vaccine development Annette Fox WHO Collaborating Centre for Reference and Research on Influenza at The Peter Doherty Institute for Infection and Immunity 1 Outline Why
More informationClinical Trials of Pandemic Vaccines: Key Issues. John Treanor University of Rochester Rochester, NY
Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY Inactivated vaccine approach Proven technology Used successfully in 1957 and 1968 Abundant efficacy data
More informationNature Immunology: doi: /ni Supplementary Figure 1. Infection strategy.
Supplementary Figure 1 Infection strategy. To test the antibody responses against influenza viruses, animals were sequentially infected with two divergent strains of the same subtype. For H1N1 infections,
More informationIncorporating virologic data into seasonal and pandemic influenza vaccines
Incorporating virologic data into seasonal and pandemic influenza vaccines Kanta Subbarao WHO Collaborating Centre for Reference and Research on Influenza & Department of Microbiology and Immunology, University
More informationInfluenza or flu is a
Clinical and Research Area Infectious Diseases Influenza Virus Types A and B Influenza or flu is a respiratory illness that is caused by influenza viruses. Influenza viruses type A and type B cause seasonal
More informationThe "Flu" a case of low fever and sniffles that keeps you home in bed for a day a gastrointestinal upset ("stomach flu")
The "Flu" Influenza is a viral infection of the lungs characterized by fever, cough, and severe muscle aches. In the elderly and infirm, it is a major cause of disability and death (often as a result of
More informationACIP Meeting June 22, 2016 Influenza Session: Key Points
Update: CDC s Advisory Committee on Immunization Practices (ACIP) voted in favor of an interim recommendation that live attenuated influenza vaccine (LAIV), also known as the nasal spray flu vaccine, should
More informationJan C. de Jong, 1 * Walter E.P. Beyer, 1 Abraham M. Palache, 2 Guus F. Rimmelzwaan, 1 and Albert D.M.E. Osterhaus 1 KEY WORDS:
Journal of Medical Virology 61:94 99 (2000) Mismatch Between the 1997/1998 Influenza Vaccine and the Major Epidemic A(H3N2) Virus Strain as the Cause of an Inadequate Vaccine-Induced Antibody Response
More informationNASDAQ:NVAX Novavax, Inc. All rights reserved.
Novavax vaccine induced improved immune responses against homologous and drifted A(H3N2) viruses in older adults compared to egg-based, high-dose, influenza vaccine World Vaccine Congress April 4, 2018
More informationWhat are ADCC antibodies? Work on influenza ADCC antibodies Greenberg et al, Hashimoto et al. First describes Fluspecific
14/7/214 Acknowledgement antibodies against diverse influenza strains: Implications for universal vaccination Sinth Jegaskanda PhD Prof Stephen Kent University of Melbourne What are antibodies? Work on
More information100 years of Influenza Pandemic and the prospects for new influenza vaccines
100 years of Influenza Pandemic and the prospects for new influenza vaccines Dr John McCauley Director, WHO Collaborating Centre for Reference and Research on influenza The Francis Crick Institute London
More informationMin Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention. June 18, 2015 NIBSC
Workshop on Immunoassay Standardization for Universal Flu Vaccines Min Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention June 18, 2015 NIBSC 1 Multiple Immune Mechanisms Contribute
More informationActive and Passive Immunization for Avian Influenza Virus Infections
NIAID Active and Passive Immunization for Avian Influenza Virus Infections Kanta Subbarao, MD, MPH Laboratory of Infectious Diseases NIAID, NIH Immortalizing H5 HA-Specific Memory B Cells Collection of
More informationThe A (H5N1) highly pathogenic avian influenza (HPAI) virus
Characterization of Reverse Genetics-Derived Cold-Adapted Master Donor Virus A/Leningrad/134/17/57 (H2N2) and Reassortants with H5N1 Surface Genes in a Mouse Model Irina Isakova-Sivak, a,b Li-Mei Chen,
More informationWHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines: Update
WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines: Update 23 July 2009 Introduction This document updates guidance 1 from the World
More informationQuestions and Answers
Questions and Answers Recommended composition of influenza virus vaccines for use in the southern hemisphere 2016 influenza season and development of candidate vaccine viruses for pandemic preparedness
More informationHigh Dose Inactivated Influenza Vaccines. Robert L. Atmar, M.D. Baylor College of Medicine WHO Meeting January 2013
High Dose Inactivated Influenza Vaccines Robert L. Atmar, M.D. Baylor College of Medicine WHO Meeting January 2013 Increased (High) Dose IVV A Brief History Dose response for immunogenicity & injection
More informationInfluenza Prevention Update
Influenza Prevention Update Dean A. Blumberg, MD, FAAP Disclosure speakers bureau: sanofi pasteur, Merck Discussion off label use of FDA approved vaccines Influenza Prevention Update Seasonal influenza
More information7/14/2014. Multiple immune effector mechanisms contribute to protection influenza. What is a correlate of protection?
What is a correlate of protection? Immunological Assessment of Influenza Vaccines and Correlates of Protection Jacqueline Katz Influenza Division Centers for Disease Control and Prevention Defined immune
More informationReview on vectored influenza vaccines. Sarah Gilbert Jenner Institute Oxford
Review on vectored influenza vaccines Sarah Gilbert Jenner Institute Oxford Viral Vectored Influenza Vaccines Can be used to induce antibodies against HA Will also boost CD4 + T cell responses against
More informationImproving Influenza vaccines: Looking ahead
Improving Influenza vaccines: Looking ahead Gerd Sutter gerd.sutter@lmu.de ESWI Flu Summit - Brussels 30.09.2015 First 20th century pandemic - The Spanish Flu Courtesy: A. Garcia-Sastre Influenza A/CDC/1918
More informationInfluenza Epidemiology,Treatment, and Prevention. Matt Zahn, MD Medical Director Epidemiology and Assessment Orange County Health Care Agency
Influenza Epidemiology,Treatment, and Prevention Matt Zahn, MD Medical Director Epidemiology and Assessment Orange County Health Care Agency Orange County Population of 3,010,232 60.8% White 33.7% Hispanic
More information24 26 January 2013, Hong Kong SAR, CHINA. TITLE from VIEW and SLIDE MASTER February 27, 2013
The first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses 24 26 January 2013, Hong Kong SAR, CHINA 1 TITLE
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationChallenges and Solutions for the Next Generation of Vaccines: Jonathan Liu Luis Maranga Sachin Mani Richard Schwartz
Challenges and Solutions for the Next Generation of Vaccines: Development of fcell llculture-based dlive Attenuated t Influenza Vaccine VACCINE TECHNOLOGY II June 1, 2008 Albufeira (near Faro), Algarve,
More informationReview of Avian Influenza A(H5N1) for WHO SAGE
Review of Avian Influenza A(H5N1) for WHO SAGE SAGE Geneva November 2013 Joseph Bresee, MD Epidemiology and Prevention Branch Influenza Division National Center for Immunization and Respiratory Diseases
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/35908 holds various files of this Leiden University dissertation Author: Soema, Peter Title: Formulation of influenza T cell peptides : in search of a universal
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationRecommended composition of influenza virus vaccines for use in the influenza season
Recommended composition of influenza virus vaccines for use in the 2006 2007 influenza season This recommendation relates to the composition of vaccines for the forthcoming influenza season in the northern
More informationCurrent Vaccines: Progress & Challenges. Influenza Vaccine what are the challenges?
Current Vaccines: Progress & Challenges Influenza Vaccine what are the challenges? Professor John S. Tam The Hong Kong Polytechnic University Asia-Pacific Alliance for the Control of Influenza (APACI)
More informationInfluenza surveillance and pandemic preparedness - a global challenge Anne Kelso
Influenza surveillance and pandemic preparedness - a global challenge Anne Kelso WHO Collaborating Centre for Reference and Research on Influenza Melbourne, Australia Three global health challenges 243
More informationAI/PI UPDATE. September 2007 Defense Health Board
AI/PI UPDATE September 2007 Defense Health Board LTC Wayne E. Hachey DO, MPH Office of the Assistant Secretary of Defense (Health Affairs) Force Health Protection & Readiness PP0066 H5N1 Avian Influenza
More informationCenters for Disease Control and Prevention U.S. INFLUENZA SEASON SUMMARY*
1 of 8 11/8/2012 1:36 PM Centers for Disease Control and Prevention 2005-06 U.S. INFLUENZA SEASON SUMMARY* NOTE: This document is provided for historical purposes only and may not reflect the most accurate
More informationInfluenza Genome Sequencing Project Proposal
Date of Proposal (MM/DD/YY): 06/13/12 TITLE: Role of the Untranslated Regions of the Influenza A Virus Replication and Vaccines Purpose/Objective-please provide a brief one to two paragraph description
More informationNanoparticulate Vaccine Design: The VesiVax System
Nanoparticulate Vaccine Design: The VesiVax System Gary Fujii, Ph.D. President and CEO Molecular Express, Inc. May 16, 2006 Orlando, Florida Influenza Each year up to 20% of the world's population contracts
More informationHemagglutinin-stalk specific antibodies: How to induce them and how to measure them
Immunodominant head domain Stalk domain Hemagglutinin-stalk specific antibodies: How to induce them and how to measure them Florian Krammer Icahn School of Medicine at Mount Sinai May 5 th 2014 2 nd WHO
More informationSAFETY, EFFICACY, AND USE OF INACTIVATED INFLUENZA VACCINE IN CHILDREN * Kathryn M. Edwards, MD RANDOMIZED TRIALS COMPARING INACTIVATED
SAFETY, EFFICACY, AND USE OF INACTIVATED INFLUENZA VACCINE IN CHILDREN * Kathryn M. Edwards, MD ABSTRACT A review of selected clinical trials of influenza vaccine shows that the vaccines are safe and effective
More informationVaccine. Design and Manufacturing. Liting Bi. https://en.wikipedia.org/wiki/vaccine
Vaccine Design and Manufacturing Liting Bi https://en.wikipedia.org/wiki/vaccine 1 Outline Vaccine Intro. 4 Vaccine Types 2 Manufacturing Methods 2 Tests & Applications Take-home messages 2 https://www.youtube.com/watch?v=t_me5ef0ne4
More information10/6/2014. INFLUENZA: Why Should We Take The Vaccine? OUTLINE INFLUNZA VIRUS INFLUENZA VIRUS INFLUENZA VIRUS
INFLUENZA: Why Should We Take The Vaccine? Baptist Hospital Baptist Children s Hospital Doctors Hospital J. Milton Gaviria, MD, FACP October 17, 2014 Homestead Hospital Mariners Hospital Baptist Cardiac
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationInfluenza Update. Lisa Grohskopf, MD, MPH Influenza Division, CDC. NAICP Call 6 October 2015
Influenza Update Lisa Grohskopf, MD, MPH Influenza Division, CDC NAICP Call 6 October 2015 National Center for Immunization and Respiratory Diseases Influenza Division Overview Surveillance update ACIP
More informationPredicting the future
Swine influenza A viruses: a more global picture Predicting the future Dr Nicola S. Lewis BSc BVetMed PhD MRCVS Dr Nicola S. Lewis BSc BVetMed PhD MRCVS Centre for for Pathogen Evolution and WHO Collaborating
More informationReceived 7 September 2006/Accepted 11 October 2006
JOURNAL OF VIROLOGY, Jan. 2007, p. 215 228 Vol. 81, No. 1 0022-538X/07/$08.00 0 doi:10.1128/jvi.01957-06 Copyright 2007, American Society for Microbiology. All Rights Reserved. Comparison of the Influenza
More informationTechnology Overview. Summary
Live Attenuated Influenza Vaccines with Altered NS1 Technology Overview Summary Transformative Technology: Live attenuated influenza vaccines (LAIVs) with precise, genetically stable truncations of the
More informationINFLUENZA VIRUS. INFLUENZA VIRUS CDC WEBSITE
INFLUENZA VIRUS INFLUENZA VIRUS CDC WEBSITE http://www.cdc.gov/ncidod/diseases/flu/fluinfo.htm 1 THE IMPACT OF INFLUENZA Deaths: PANDEMICS 1918-19 S p a n is h flu 5 0 0,0 0 0 U S 2 0,0 0 0,0 0 0 w o rld
More informationCross-Reactivity to Field Isolates of Canine Influenza Virus by a Killed Canine Influenza Virus (H3N8, Iowa05) Vaccine
Cross-Reactivity to Field Isolates of Canine Influenza Virus by a Killed Canine Influenza Virus (H3N8, Iowa05) Vaccine Nancee Oien, B.S., M.S. a Sally Mattern, B.S a Jaime Brozowski, B.S., M.S. b Janet
More informationph1n1 H3N2: A Novel Influenza Virus Reassortment
ph1n1 H3N2: A Novel Influenza Virus Reassortment Jonathan Gubbay Medical Microbiologist Public Health Laboratory Public Health Ontario June 16, 2011 ph1n1 H3N2 Reassortment: Talk Overview Explain strain
More information2007 ACIP Recommendations for Influenza Vaccine. Anthony Fiore, MD, MPH Influenza Division, NCIRD, CDC
2007 ACIP Recommendations for Influenza Vaccine Anthony Fiore, MD, MPH Influenza Division, NCIRD, CDC National Influenza Vaccine Summit April 19, 2007 Recommendation Changes for Influenza Vaccination:
More informationDr Olga Pleguezuelos CSO and Project Manager at SEEK
Dr Olga Pleguezuelos CSO and Project Manager at SEEK Imutex Limited, formed in 2016, is a joint venture between SEEK Group and hvivo to accelerate the development of a Mosquito Vaccine (AGS-v) and Broad-
More informationMA Adult Immunization Coaltion Flu Update September 28, 2016
MA Adult Immunization Coaltion Flu Update September 28, 2016 Susan M. Lett, MD, MPH Medical Director, Immunization Program Division of Epidemiology and Immunization Massachusetts Department of Public Health
More informationGSK s Adjuvanted Influenza Vaccines The Taming of the Flu
GSK s Adjuvanted Influenza Vaccines The Taming of the Flu JITMM, Bangkok, October 2008 Bruce L. Innis, MD Global Clinical Research and Development GlaxoSmithKline Biologicals 1 Annual Burden of Influenza
More information14/07/2014. Disclosures and acknowledgements. Study Design (NCT ) Rationale for a QIV efficacy study in children
/7/ Disclosures and acknowledgements I am employed by the GlaxoSmithKline group of companies and I own stocks/options of the GlaxoSmithKline group of companies; my travel to this meeting was funded by
More informationUS Influenza Vaccine Effectiveness Influenza Clinical Investigation for Children (ICICLE) Study
215-16 US Influenza Vaccine Effectiveness Influenza Clinical Investigation for Children (ICICLE) Study Chris Ambrose, MD Vice President, Infectious Disease, US Medical Affairs 22 June 216 Summary of LAIV
More informationAcute respiratory illness This is a disease that typically affects the airways in the nose and throat (the upper respiratory tract).
Influenza glossary Adapted from the Centers for Disease Control and Prevention, US https://www.cdc.gov/flu/glossary/index.htm and the World Health Organization http://www.wpro.who.int/emerging_diseases/glossary_rev_sept28.pdf?ua=1
More informationCenters for Disease Control and Prevention U.S. INFLUENZA SEASON SUMMARY*
1 of 6 11/8/2012 1:35 PM Centers for Disease Control and Prevention 2004-05 U.S. INFLUENZA SEASON SUMMARY* NOTE: This document is provided for historical purposes only and may not reflect the most accurate
More informationH5N1 Vaccine-Specific B Cell Responses in Ferrets Primed with Live Attenuated Seasonal Influenza Vaccines
-Specific B Cell Responses in Ferrets Primed with Live Attenuated Seasonal Influenza Vaccines Xing Cheng 1., Michael Eisenbraun 1.,QiXu 1, Helen Zhou 1, Deepali Kulkarni 1, Kanta Subbarao 2, George Kemble
More informationAvian influenza and pandemic threats
Avian influenza and pandemic threats Philippe BUCHY MD, PhD Head of Virology Unit Director NIC Cambodia Vaccinology 2013 Bangkok, 11-13 November 2013 Influenza viruses Influenza viruses (Orthomyxoviridae)
More informationUpdate on Influenza Vaccines, the Influenza Season, and the Impact of Vaccination on Influenza Disease Burden
National Center for Immunization & Respiratory Diseases Update on Influenza Vaccines, the 2017 2018 Influenza Season, and the Impact of Vaccination on Influenza Disease Burden Melissa Rolfes, PhD MPH Epidemiologist
More informationInfluenza Virus Genotypes Circulating In Central Greece During And Vaccine Strain Match
ISPUB.COM The Internet Journal of Microbiology Volume 13 Number 1 Influenza Virus Genotypes Circulating In Central Greece During 2012-2014 And Vaccine Strain Match E Plakokefalos, A Vontas, Z Florou, G
More informationInfluenza A(H1N1) aka Swine Flu. IAP ACVIP statement on ongoing outbreak of H1N1 in India. Situational analysis: Historical perspectives
Influenza A(H1N1) aka Swine Flu IAP ACVIP statement on ongoing outbreak of H1N1 in India Situational analysis: Historical perspectives H1N1 pandemic in 2009-10: The pandemic of A (H1N1) was first reported
More informationImpact of influenza vaccination on influenza antibody response and unplanned hospital admissions
Impact of influenza vaccination on influenza antibody response and unplanned hospital admissions among community-dwelling Chinese elderly in Hong Kong A randomised controlled trial Dr. L. W. Chu Consultant,
More informationBlocking Interhost Transmission of Influenza Virus by Vaccination in the Guinea Pig Model
JOURNAL OF VIROLOGY, Apr. 2009, p. 2803 2818 Vol. 83, No. 7 0022-538X/09/$08.00 0 doi:10.1128/jvi.02424-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Blocking Interhost Transmission
More informationPrevalence of Antibodies against Seasonal Influenza A and B Viruses in Children in Netherlands
CLINICAL AND VACCINE IMMUNOLOGY, Mar. 2011, p. 469 476 Vol. 18, No. 3 1556-6811/11/$12.00 doi:10.1128/cvi.00396-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Prevalence of
More informationequal groups. Children of the first group received vaccine, whereas those in the other received an indistinguishable
INFECTION AND IMMNITY, June 1984, p. 734-739 19-9567/84/6734-6$2./ Copyright 1984, American Society for Microbiology Vol. 44, No. 3 Recombinant Cold-Adapted Attenuated Influenza A Vaccines for se in Children:
More informationThe DBA.2 Mouse Is Susceptible to Disease following Infection with a Broad, but Limited, Range of Influenza A and B Viruses
JOURNAL OF VIROLOGY, Dec. 2011, p. 12825 12829 Vol. 85, No. 23 0022-538X/11/$12.00 doi:10.1128/jvi.05930-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. The DBA.2 Mouse Is Susceptible
More informationVirology 412 (2011) Contents lists available at ScienceDirect. Virology. journal homepage:
Virology 412 (2011) 297 305 Contents lists available at ScienceDirect Virology journal homepage: www.elsevier.com/locate/yviro Genetic bases of the temperature-sensitive phenotype of a master donor virus
More informationWhat is influenza virus? 13,000 base RNA genome: 1/ the size of the human genome
What is influenza virus? 13,000 base RNA genome: 1/246153 the size of the human genome CDC Principles of Virology, 4e Neumann et al. Nature. 2009. Influenza virus is one of the most deadly viral pathogens
More informationE.J. Remarque & G. Koopman. Confiden'al 2
EDUcate influenza VACcine A Combinatorial immunization strategy to educate the immune system towards cross recognition and coverage against antigenic drift in seasonal influenza virus exposure Confiden'al
More informationAntigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness
Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness September 2014 The development of representative candidate influenza
More informationInfluenza: The past, the present, the (future) pandemic
Influenza: The past, the present, the (future) pandemic Kristin Butler, MLS (ASCP) cm Department of Clinical Laboratory Sciences Louisiana Health Sciences Center - Shreveport Fall 2017 Objectives 1) Detail
More informationCorrelates of Protection for Flu vaccines and Assays Overview. by Simona Piccirella, PhD Chief Executive Officer
Correlates of Protection for Flu vaccines and Assays Overview by Simona Piccirella, PhD Chief Executive Officer Company Overview: VisMederi is an Italian private small enterprise established in 2009 and
More informationLive attenuated Influenza vaccine
Serum Institute of India Pvt. Ltd. Live attenuated Influenza vaccine Parikshit Tyagi, MSc, PhD Sr. Manager, Quality Control Introduction founded in 1966 by Dr. Cyrus Poonawalla with the aim of manufacturing
More informationWhat s New in Flu? An Update on Influenza Prevention and Treatment
What s New in Flu? An Update on Influenza Prevention and Treatment Kathryn M. Edwards MD Sarah H. Sell and Cornelius Vanderbilt Professor of Pediatrics Vanderbilt University Nashville, TN, USA Disclosures
More informationModeling the Antigenic Evolution of Influenza Viruses from Sequences
Modeling the Antigenic Evolution of Influenza Viruses from Sequences Taijiao Jiang Center of Systems Medicine, Chinese Academy of Medical Sciences Suzhou Institute of Systems Medicine October 8-10, 2015.
More information- indicates information is not applicable
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FLUMIST QUADRIVALENT safely and effectively. See full prescribing information for FLUMIST QUADRIVALENT.
More informationGlobal Influenza Virus Surveillance and WHO Influenza Vaccine Virus Recommendations for the Northern Hemisphere Influenza Season
Global Influenza Virus Surveillance and WHO Influenza Vaccine Virus Recommendations for the Northern Hemisphere 2015-16 Influenza Season Jacqueline Katz, Ph. D. Deputy Director (acting), Influenza Division
More informationInfluenza Vaccines. Wilbur H. Chen, MD, MS Associate Professor of Medicine April 19, 2017 CVD
Influenza Vaccines Wilbur H. Chen, MD, MS Associate Professor of Medicine April 19, 2017 Overview 1) Biology & Epidemiology of Influenza (and other Respiratory Viruses) 2) Currently Approved Influenza
More informationLars R. Haaheim ( ) PhD, Professor Emeritus, University of Bergen, Norway
Lars R. Haaheim (1945-2011) PhD, Professor Emeritus, University of Bergen, Norway Licensing requirements a personal perspective John M Wood Summer School on Influenza, Siena August 1-5 2011 National Institute
More informationGene Vaccine Dr. Sina Soleimani
Gene Vaccine Dr. Sina Soleimani Human Viral Vaccines Quality Control Laboratory (HVVQC) Titles 1. A short Introduction of Vaccine History 2. First Lineage of Vaccines 3. Second Lineage of Vaccines 3. New
More informationEvaluation of Live Avian-Human Reassortant Influenza A H3N2
JOURNAL OF CLINICAL MICROBIOLOGY, May 1986, p. 852-857 0095-1137/86/050852-06$02.00/0 Copyright 1986, American Society for Microbiology Vol. 23, No. 5 Evaluation of Live Avian-Human Reassortant Influenza
More informationHow flu vaccines work. Universal Influenza Vaccination of Children - the UK experience. 2 parts to an infection.. Direct effects.
Bristol Children s Vaccine Centre Universal Influenza Vaccination of Children - the UK experience @adamhfinn DIPS, Korsør 9 th November 018 How flu vaccines work Specific (on target) direct effects indirect
More informationVaccine Technology II June 1-6, 2008 (Albufeira, Algarve, Portugal) FluBlok, A High Dose Recombinant Hemagglutinin Influenza Vaccine.
Vaccine Technology II June 1-6, 2008 (Albufeira, Algarve, Portugal) FluBlok, A High Dose Recombinant Hemagglutinin Influenza Vaccine Manon Cox June 2, 2008 A Vaccine Company for the 21st Century Making
More information2/27/2013. Dr. S. Broor All India Institute of Medical Sciences New Delhi India
Dr. S. Broor All India Institute of Medical Sciences New Delhi India 1 Delhi Ballabgarh 2 Urban tertiary care hospital Rural Primary and Secondary care All India Institute of Medical Sciences (AIIMS) Rural
More informationEvolution of influenza
Evolution of influenza Today: 1. Global health impact of flu - why should we care? 2. - what are the components of the virus and how do they change? 3. Where does influenza come from? - are there animal
More informationOverview of seasonal Influenza Vaccines and Future Directions
Overview of seasonal Influenza Vaccines and Future Directions San Jose, Costa Rica January 2013 Joseph Bresee Epidemiology and Prevention Branch Influenza Division National Center for Immunization and
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationInfluenza A and B viruses infect 5 to 15% of the global population
Comparative Study of Influenza Virus Replication in MDCK Cells and in Primary Cells Derived from Adenoids and Airway Epithelium Natalia A. Ilyushina, a Mine R. Ikizler, b Yoshihiro Kawaoka, c,d,e Larisa
More informationPatricia Fitzgerald-Bocarsly
FLU Patricia Fitzgerald-Bocarsly October 23, 2008 Orthomyxoviruses Orthomyxo virus (ortho = true or correct ) Negative-sense RNA virus (complementary to mrna) Five different genera Influenza A, B, C Thogotovirus
More information